Inclusion Criteria:

- Participant is age 12 and older.

- Participant is male or is a female of childbearing potential who is surgically
sterile, 2 years postmenopausal, or practices a reliable method of contraception
(hormonal, barrier method or abstention).

- Participant failed treatment with a minimum of two antiseizure medications (used in
appropriate doses) with adequate monitoring of compliance and the effects of
treatment, as determined by the investigator.

- Participant is able to maintain an electronic diary alone or with the assistance of a
competent individual.

- Participant is able to attend clinic appointments in accordance with the study
schedule.

- Participant or parent(s) or legal representative have signed an IRB approved written
informed consent/assent. The informed consent form or specific assent form, where
required, will be signed and dated by minors.

- Participant is not currently implanted with an RNS Neurostimulator or NeuroPace Leads.

- In the investigator's opinion, participant is able to tolerate a neurosurgical
procedure.

- Participant with a confirmed diagnosis of idiopathic generalized epilepsy experiencing
primary generalized tonic-clonic seizures, with or without myoclonic or absence
seizures, consistent with the International League against Epilepsy Revised
Classification of Seizures (2017).

- Participant has had 2 or more generalized tonic-clonic seizures during the two month
retrospective baseline.

- Participant has had a routine electroencephalogram (EEG) within 2 years prior to
enrollment with electroencephalographic features consistent with idiopathic
generalized epilepsy; other concomitant anomalies must be explained by adequate past
medical history.

- Participant has been on a stable antiseizure medication (ASM) regimen during the two
month retrospective baseline and is willing to remain on a stable ASM regimen during
the prospective Baseline and throughout the Effectiveness Evaluation Period, if
medically possible; rescue benzodiazepine medications for acute seizure clusters are
permitted.

- Participant has undergone computed tomography (CT) or magnetic resonance imaging (MRI)
within 10 years prior to enrollment that ruled out a progressive cause of epilepsy or
an abnormality likely to be associated with focal-onset seizures.

- Participant does not have a vagus nerve stimulator (VNS, LivaNova) or Participant's
VNS is OFF during the two month retrospective baseline and participant is willing to
keep the VNS off during the study.

Exclusion Criteria:

- Participant is pregnant.

- Participant is participating in a therapeutic investigational drug or other device
study.

- Participant is implanted with an electronic medical device that delivers electrical
energy to the brain.

- Participant requires procedures that are contraindicated based on current RNS System
labeling.

- Participant has been diagnosed with active psychosis, major depression or suicidal
ideation in the preceding year. Participants with post-ictal psychiatric symptoms need
not be excluded.

- In the opinion of the investigator, the participant has a clinically significant or
unstable medical condition (including alcohol and/or drug abuse) or a progressive
central nervous system disease.

- Participant has a history of partial-onset seizures or EEG findings within the past 2
years indicative of partial-onset or symptomatic generalized abnormalities.

- Participant has been diagnosed with psychogenic or non-epileptic seizures in the
preceding year.

- Participant has experienced unprovoked status epilepticus in the preceding year.

- Participant is taking any anticoagulants.

Eligibility last updated 9/19/22. Questions regarding updates should be directed to the study team contact.